Nawar, M.F.; Selim, A.A.; Essa, B.M.; El-Daoushy, A.F.; Swidan, M.M.; Chambers, C.G.; Al Qahtani, M.H.; Smith, C.J.; Sakr, T.M.
Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects. Cancers 2025, 17, 3055.
https://doi.org/10.3390/cancers17183055
AMA Style
Nawar MF, Selim AA, Essa BM, El-Daoushy AF, Swidan MM, Chambers CG, Al Qahtani MH, Smith CJ, Sakr TM.
Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects. Cancers. 2025; 17(18):3055.
https://doi.org/10.3390/cancers17183055
Chicago/Turabian Style
Nawar, Mohamed F., Adli A. Selim, Basma M. Essa, Alaa F. El-Daoushy, Mohamed M. Swidan, Claudia G. Chambers, Mohammed H. Al Qahtani, Charles J. Smith, and Tamer M. Sakr.
2025. "Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects" Cancers 17, no. 18: 3055.
https://doi.org/10.3390/cancers17183055
APA Style
Nawar, M. F., Selim, A. A., Essa, B. M., El-Daoushy, A. F., Swidan, M. M., Chambers, C. G., Al Qahtani, M. H., Smith, C. J., & Sakr, T. M.
(2025). Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects. Cancers, 17(18), 3055.
https://doi.org/10.3390/cancers17183055
